Fig. 3

Glycosylation modification and tetraspanins on the surface of EVs. a Glycosylation modifications are altered in cancer cells. (Based on Shimoda et al. [18]). b Natural killer (NK) cell-derived EVs contain CD63 and CD81, but not CD9. On the other hand, platelet-derived EVs contain CD9 and CD63 but scarcely contain CD81 [20]. c There are HeLa cell-derived EVs that are CD9 single positive, CD63 single positive, and double positive [21]. d In amniotic fluid-derived EVs, some contain only one CD9, CD63, or CD81, while others contain multiple of them [22].